Caladrius Biosciences Company Profile (NASDAQ:CLBS)

About Caladrius Biosciences (NASDAQ:CLBS)

Caladrius Biosciences logoCaladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development. The Company's product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company's T Regulatory Cell Technology is applicable to multiple autoimmune and allergic diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CLBS
  • CUSIP: N/A
  • Web: www.caladrius.com
Average Prices:
  • 50 Day Moving Avg: $4.81
  • 200 Day Moving Avg: $4.37
  • 52 Week Range: $2.65 - $7.79
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.06
  • P/E Growth: -0.03
Profitability:
  • Net Margins: -183.36%
  • Return on Equity: -270.38%
  • Return on Assets: -60.07%
Debt:
  • Debt-to-Equity Ratio: 0.36%
  • Current Ratio: 1.62%
  • Quick Ratio: 1.62%
Misc:
  • Average Volume: 111,402 shs.
  • Beta: 1.01
 

Frequently Asked Questions for Caladrius Biosciences (NASDAQ:CLBS)

What is Caladrius Biosciences' stock symbol?

Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS."

How were Caladrius Biosciences' earnings last quarter?

Caladrius Biosciences Inc (NASDAQ:CLBS) released its earnings results on Thursday, May, 18th. The company reported ($1.12) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by $0.40. The company had revenue of $7.92 million for the quarter, compared to analysts' expectations of $9.50 million. Caladrius Biosciences had a negative return on equity of 270.38% and a negative net margin of 183.36%. View Caladrius Biosciences' Earnings History.

Where is Caladrius Biosciences' stock going? Where will Caladrius Biosciences' stock price be in 2017?

2 brokerages have issued twelve-month target prices for Caladrius Biosciences' shares. Their predictions range from $6.50 to $7.00. On average, they expect Caladrius Biosciences' stock price to reach $6.75 in the next year. View Analyst Ratings for Caladrius Biosciences.

Who are some of Caladrius Biosciences' key competitors?

Who owns Caladrius Biosciences stock?

Caladrius Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (0.00%), Renaissance Technologies LLC (0.00%), KCG Holdings Inc. (0.00%) and Geode Capital Management LLC (0.00%). Company insiders that own Caladrius Biosciences stock include David J Mazzo, Eric Wei and Robert S Vaters. View Institutional Ownership Trends for Caladrius Biosciences.

Who bought Caladrius Biosciences stock? Who is buying Caladrius Biosciences stock?

Caladrius Biosciences' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Renaissance Technologies LLC, KCG Holdings Inc. and Geode Capital Management LLC. Company insiders that have bought Caladrius Biosciences stock in the last two years include David J Mazzo and Robert S Vaters. View Insider Buying and Selling for Caladrius Biosciences.

How do I buy Caladrius Biosciences stock?

Shares of Caladrius Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Caladrius Biosciences stock cost?

One share of Caladrius Biosciences stock can currently be purchased for approximately $4.69.

Analyst Ratings

Consensus Ratings for Caladrius Biosciences (NASDAQ:CLBS) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.75 (43.92% upside)

Analysts' Ratings History for Caladrius Biosciences (NASDAQ:CLBS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017HC WainwrightSet Price TargetBuy$7.00LowView Rating Details
11/9/2016Chardan CapitalReiterated RatingBuy$6.50N/AView Rating Details
5/14/2016Maxim GroupReiterated RatingHoldN/AView Rating Details
4/30/2016Rodman & RenshawUpgradeBuyN/AView Rating Details
1/26/2016AegisReiterated RatingBuyN/AView Rating Details
9/24/2015WBB SecuritiesReiterated RatingBuy$7.00N/AView Rating Details
8/7/2015Benchmark Co.DowngradeBuy -> Hold$12.00 -> $2.00N/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Caladrius Biosciences (NASDAQ:CLBS)
Earnings by Quarter for Caladrius Biosciences (NASDAQ:CLBS)
Earnings History by Quarter for Caladrius Biosciences (NASDAQ:CLBS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/18/2017Q1 2017($0.72)($1.12)$9.50 million$7.92 millionViewN/AView Earnings Details
3/17/2017Q4 2016($0.80)($0.73)$6.30 million$10.18 millionViewN/AView Earnings Details
11/7/2016Q3($1.55)($1.09)$7.70 million$9.32 millionViewListenView Earnings Details
8/9/2016Q216($1.75)($1.33)$7.53 million$8.30 millionViewN/AView Earnings Details
3/15/2016Q4($0.28)($0.59)$7.67 million$7.60 millionViewListenView Earnings Details
11/5/2015Q3 2015($0.30)($0.21)$6.00 million$5.89 millionViewN/AView Earnings Details
8/6/2015Q215($0.32)($0.31)$5.20 million$5.87 millionViewN/AView Earnings Details
10/30/2014Q3 2014($0.41)($0.44)$4.00 million$4.12 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.28)($0.38)$4.70 million$4.49 millionViewN/AView Earnings Details
11/14/2012Q312($0.05)($0.06)$3.50 million$4.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Caladrius Biosciences (NASDAQ:CLBS)
Current Year EPS Consensus Estimate: $-3.14 EPS
Next Year EPS Consensus Estimate: $-2.28 EPS

Dividends

Dividend History for Caladrius Biosciences (NASDAQ:CLBS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Caladrius Biosciences (NASDAQ:CLBS)
Insider Ownership Percentage: 13.10%
Institutional Ownership Percentage: 19.42%
Insider Trades by Quarter for Caladrius Biosciences (NASDAQ:CLBS)
Institutional Ownership by Quarter for Caladrius Biosciences (NASDAQ:CLBS)
Insider Trades by Quarter for Caladrius Biosciences (NASDAQ:CLBS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/7/2017Eric WeiDirectorSell6,575$4.77$31,362.75View SEC Filing  
2/6/2017Eric WeiDirectorSell8,425$4.61$38,839.25View SEC Filing  
7/1/2016Eric WeiDirectorSell87,500$0.60$52,500.00View SEC Filing  
6/24/2016Eric WeiDirectorSell22,698$0.55$12,483.90View SEC Filing  
8/17/2015David J MazzoCEOBuy20,000$1.40$28,000.00View SEC Filing  
8/11/2015Robert S VatersCFOBuy81,000$1.24$100,440.00View SEC Filing  
12/9/2014Steven S MyersDirectorBuy20,000$3.56$71,200.00View SEC Filing  
12/8/2014Rimasia Capital Partners ManagDirectorSell16,060$3.75$60,225.00View SEC Filing  
12/3/2014Rimasia Capital Partners ManagDirectorSell12,000$4.01$48,120.00View SEC Filing  
12/1/2014Steven S MyersDirectorBuy10,000$3.92$39,200.00View SEC Filing  
11/25/2014Steven M KloskDirectorBuy10,000$3.99$39,900.00View SEC Filing  
11/24/2014Andrew L PecoraInsiderBuy12,500$4.01$50,125.00View SEC Filing  
11/24/2014Steven S MyersDirectorBuy19,800$3.94$78,012.00View SEC Filing  
12/12/2013Richard BermanDirectorSell12,218$5.99$73,185.82View SEC Filing  
12/9/2013Rimasia Capital Partners Managmajor shareholderSell12,530$6.37$79,816.10View SEC Filing  
12/28/2012Richard J BermanDirectorSell149,306$0.59$88,090.54View SEC Filing  
9/18/2012Richard J BermanDirectorSell36,000$0.69$24,840.00View SEC Filing  
9/17/2012Rimasia Capital Partners ManagMajor ShareholderSell30,000$0.71$21,300.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Caladrius Biosciences (NASDAQ:CLBS)
Latest Headlines for Caladrius Biosciences (NASDAQ:CLBS)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Caladrius Biosciences, Inc. : May 23, 2017
finance.yahoo.com - May 23 at 12:48 PM
americanbankingnews.com logoZacks Investment Research Upgrades Caladrius Biosciences Inc (CLBS) to "Hold"
www.americanbankingnews.com - May 22 at 6:26 PM
finance.yahoo.com logoCaladrius Biosciences, Inc. :CLBS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 22, 2017
finance.yahoo.com - May 22 at 12:35 PM
americanbankingnews.com logoCaladrius Biosciences Inc (CLBS) PT Set at $7.00 by HC Wainwright
www.americanbankingnews.com - May 19 at 8:29 PM
finance.yahoo.com logoCaladrius Biosciences Closes the Sale of its Remaining Interest in PCT to Hitachi Chemical for $75 Million
finance.yahoo.com - May 18 at 4:17 PM
globenewswire.com logoCaladrius Biosciences Announces 2017 First Quarter Financial Results - GlobeNewswire (press release)
globenewswire.com - May 17 at 11:38 AM
americanbankingnews.com logoCaladrius Biosciences Inc (CLBS) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 17 at 12:52 AM
finance.yahoo.com logoCaladrius Biosciences Announces 2017 First Quarter Financial Results
finance.yahoo.com - May 15 at 6:30 PM
americanbankingnews.com logoCaladrius Biosciences Inc (CLBS) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 15 at 5:42 PM
americanbankingnews.com logoCaladrius Biosciences Inc (CLBS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 9 at 6:24 PM
finance.yahoo.com logoCaladrius Biosciences to Host 2017 First Quarter Financial Results Conference Call on May 18, 2017 at 5:00 p.m. Eastern Time
finance.yahoo.com - May 9 at 4:20 PM
americanbankingnews.com logoCaladrius Biosciences (CLBS) Receiving Somewhat Positive News Coverage, Study Finds
www.americanbankingnews.com - May 4 at 1:13 AM
americanbankingnews.com logoCaladrius Biosciences Inc (CLBS) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - May 3 at 8:02 PM
americanbankingnews.com logoCaladrius Biosciences Inc (CLBS) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 1 at 3:16 PM
globenewswire.com logoCaladrius Biosciences to Participate at Upcoming May Conferences - GlobeNewswire (press release)
globenewswire.com - May 1 at 8:39 AM
finance.yahoo.com logoCaladrius Biosciences to Participate at Upcoming May Conferences
finance.yahoo.com - May 1 at 8:39 AM
americanbankingnews.com logoCaladrius Biosciences (CLBS) Earning Somewhat Positive News Coverage, Study Finds
www.americanbankingnews.com - April 21 at 2:14 PM
seekingalpha.com logoThe Strange Case Of Caladrius Biosciences - Seeking Alpha
seekingalpha.com - April 19 at 9:21 PM
americanbankingnews.com logoCaladrius Biosciences (CLBS) Earning Very Positive Press Coverage, Report Shows
www.americanbankingnews.com - April 18 at 10:20 AM
finance.yahoo.com logoShareholder Alert: Monteverde & Associates PC Announces An Investigation Of Caladrius Biosciences, Inc. - CLBS
finance.yahoo.com - April 11 at 11:46 AM
finance.yahoo.com logoCaladrius Biosciences to Hold 2017 Annual Stockholder Meeting on May 16
finance.yahoo.com - April 10 at 4:14 PM
finance.yahoo.com logoCaladrius Biosciences Announces Addition of Four Clinical Sites, Including Joslin Diabetes Center, for the Ongoing Phase 2 Study of CLBS03 in T1D
finance.yahoo.com - April 3 at 4:46 PM
biz.yahoo.com logoCALADRIUS BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 30 at 9:48 PM
finance.yahoo.com logoCALADRIUS BIOSCIENCES, INC. Financials
finance.yahoo.com - March 23 at 4:45 PM
biz.yahoo.com logoCALADRIUS BIOSCIENCES, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclos
biz.yahoo.com - March 22 at 9:00 PM
americanbankingnews.com logoCaladrius Biosciences Inc (CLBS) Given a $7.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 21 at 3:40 PM
finance.yahoo.com logoCompany News for March 20, 2017
finance.yahoo.com - March 20 at 3:33 PM
streetinsider.com logoCaladrius Biosciences (CLBS) to Sell Remaining Interest to Hitachi Chemical for $75M
www.streetinsider.com - March 18 at 4:09 PM
baystreet.ca logoCaladrius Biosciences (CLBS) Climbs as Loss Narrows
www.baystreet.ca - March 17 at 3:48 PM
rttnews.com logoCaladrius Biosciences Inc. (CLBS) Is Up Sharply After Q4 Loss Narrowed
www.rttnews.com - March 17 at 3:48 PM
seekingalpha.com logoCaladrius Biosciences' (CLBS) CEO David Mazzo on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 17 at 3:48 PM
biz.yahoo.com logoCALADRIUS BIOSCIENCES, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 17 at 3:48 PM
biz.yahoo.com logoCALADRIUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Pr
biz.yahoo.com - March 17 at 3:48 PM
finance.yahoo.com logoCaladrius Biosciences Announces 2016 Fourth Quarter and Full Year Financial Results
finance.yahoo.com - March 17 at 3:48 PM
biz.yahoo.com logoQ4 2016 Caladrius Biosciences Inc Earnings Release - Before Market Open
biz.yahoo.com - March 17 at 3:48 PM
finance.yahoo.com logoCaladrius Biosciences to Host 2016 Fourth Quarter and Full Year Financial Results Conference Call on March 17, 2017 at 8:30 am Eastern Time
finance.yahoo.com - March 13 at 12:37 PM
globenewswire.com logoCaladrius Biosciences to Present at Upcoming March Conferences - GlobeNewswire (press release)
globenewswire.com - March 2 at 4:35 PM
finance.yahoo.com logoCaladrius Biosciences to Present at Upcoming March Conferences
finance.yahoo.com - March 2 at 4:35 PM
streetinsider.com logoCaladrius Biosciences (CLBS) Awarded $12.2M CIRM Grant to ... - StreetInsider.com
www.streetinsider.com - February 23 at 9:19 PM
streetinsider.com logoCaladrius Biosciences (CLBS) Awarded $12.2M CIRM Grant to Support CLBS03 Trial
www.streetinsider.com - February 23 at 4:18 PM
finance.yahoo.com logoCaladrius Biosciences Awarded $12.2 Million Grant from CIRM in Support of Phase 2 Clinical Trial of CLBS03 to Treat Type 1 Diabetes
finance.yahoo.com - February 23 at 4:18 PM
finance.yahoo.com logo1:45 pm Caladrius Biosciences receives a grant providing up to $12.2 million for the development of CLBS03 from the California Institute for Regenerative Medicine --shares halted--
finance.yahoo.com - February 23 at 4:18 PM
globenewswire.com logoCaladrius Biosciences to Present at Upcoming February Conferences - GlobeNewswire (press release)
globenewswire.com - February 2 at 2:40 AM
finance.yahoo.com logoCaladrius Biosciences to Present at Upcoming February Conferences
finance.yahoo.com - February 1 at 4:36 PM
finance.yahoo.com logoCaladrius Biosciences Announces Addition of Three Clinical Sites, Including University of California, San Francisco, for the Ongoing Phase 2 Study of CLBS03 in T1D
finance.yahoo.com - January 25 at 5:25 PM
us.rd.yahoo.com logo4:02 pm Caladrius Biosciences has not received $6 mln from investor in previously announced private placement -- targeted to be received in Q4
us.rd.yahoo.com - January 6 at 9:45 PM
biz.yahoo.com logoCALADRIUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - January 6 at 9:45 PM
globenewswire.com logoCaladrius Biosciences to Present at Upcoming January Conferences - GlobeNewswire (press release)
globenewswire.com - January 3 at 12:53 PM
finance.yahoo.com logoCaladrius Biosciences to Present at Upcoming January Conferences
finance.yahoo.com - January 3 at 12:53 PM

Social

Chart

Caladrius Biosciences (CLBS) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff